Oncogenic Therapeutics Submits Clinical Trial Application for Dual-Targeted Anticancer Drug for Pancreatic Cancer

Onconic Therapeutics CI (Photo by Onconic Therapeutics)

[Asia Economy Reporter Chunhee Lee] Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, is challenging clinical trials for pancreatic cancer with the dual-targeted anticancer drug 'JPI-547' under development.

Onconic Therapeutics announced on the 22nd that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety for JPI-547, a dual-inhibitor targeted anticancer drug targeting PARP (poly ADP-ribose polymerase) and Tankyrase, for pancreatic cancer.

JPI-547 received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in March. Subsequently, it was designated as a rare drug in the development stage by the Ministry of Food and Drug Safety in June. In the same month, at the American Society of Clinical Oncology (ASCO), Phase 1 clinical trial results targeting multiple cancer types including ovarian and breast cancer were disclosed, drawing industry attention. Onconic Therapeutics is also pursuing clinical trials of JPI-547 for various indications targeting refractory cancers.

JPI-547 is a novel drug candidate with a dual-inhibitory mechanism that simultaneously inhibits PARP and Tankyrase. PARP is an enzyme that repairs DNA damage in cells, including cancer cell DNA, so inhibiting PARP is necessary to induce cancer cell death. Tankyrase is an enzyme essential for cancer cell formation. JPI-547’s dual inhibition of these two enzymes leads to cancer cell death, making it a promising next-generation drug candidate.

An Onconic Therapeutics representative stated, “We expect that the submission of this clinical trial application will provide an opportunity to present new possibilities as a treatment for pancreatic cancer, which has a high unmet medical need,” and added, “We hope that continuous and extensive clinical trials across multiple cancer types will help those suffering from refractory cancers.”

This content was produced with the assistance of AI translation services.